Abstract 4139
Background
Selecting which pts may benefit from ieCTs is challenging. Few prognostic indexes have been proposed so far and none qualifying as a predictor of response. The Gustave Roussy Immune Score (GRImS) identifies two prognostic categories based on three objective variables (albumin<3.5 g/dL=1; LDH>ULN=1; NLR>6=1).
Methods
We retrospectively reviewed data of all pts enrolled into ieCTs at the Humanitas Cancer Center Phase I Unit between 2014 and 2019. A large series of demographic and clinical variables were correlated with overall survival (OS) and objective response rate (ORR) through univariate and multivariate analysis (UVA; MVA). Laboratory parameters were calculated either as baseline values and as dynamic six-weeks (6wks) changes. Finally, we explored the performance of the GRImS in our cohort.
Results
A total of 111 pts (M/F:63/48; median age: 62) with advanced solid tumors treated into ieCTs have been selected. The most frequent histologies were hepatocellular carcinoma (34%), lung carcinoma (22%), glioblastomas (13%). With a median follow-up (FU) of 14.3 months (mos), the OS was 12.9 mos, and the ORR 12.6%. In the UVA ECOG PS < 1 (HR = 0.53; IC 0.30-0.94; p = 0.030) and higher baseline value of albumin (HR = 0.40; IC 0.21-0.77; p = 0.006) were significantly associated with a better OS, while baseline total protein level (OR = 1.47; IC 1.24 - 2.10; p = 0.030), and increase in lymphocytes count at 6wks (OR = 1.02; IC 1.00-1.04; p = 0.029) were predictive of response. In the MVA only higher baseline value of albumin seems to confirm its independent prognostic value (HR = 0.48; IC 0.23-1.01; p = 0.054), as well as baseline total protein level its predictive role (OR = 1.52; IC 1-2.33; p = 0.052). The GRImS resulted prognostic, with pts at low-risk (≤1) having a significant better OS compared to pts with a high-risk score (>1) (14.3 mos vs 7.3 mos; p = 0.029), but not predictive.
Conclusions
We assessed the prognostic accuracy of GRImS in our ieCTs cohort. With limitations due to small sample size, short FU and few events recorded we identified additional static and dynamic variables with a potential prognostic and predictive relevance to be further explored in larger series and to be eventually included in new scores.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Simonelli: Advisory / Consultancy: AbbVie. A. Santoro: Advisory / Consultancy: Bristol-Myers-Squibb; Advisory / Consultancy: Servier; Advisory / Consultancy: Gilead; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Eisai; Advisory / Consultancy: Bayer; Advisory / Consultancy: Merck Sharp & Dohme; Speaker Bureau / Expert testimony: Takeda; Speaker Bureau / Expert testimony: Bristol-Myers-Squibb; Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert Testimony: Abbvie; Speaker Bureau / Expert testimony: Amgen; Speaker Bureau / Expert testimony: Celgene; Speaker Bureau / Expert testimony: Servier; Speaker Bureau / Expert testimony: Gilead; Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony: Pfizer; Speaker Bureau / Expert testimony: Arqule; Speaker Bureau / Expert testimony: Lilly; Speaker Bureau / Expert testimony: SANDOZ. All other authors have declared no conflicts of interest.
Resources from the same session
3345 - Escalation plans and DNACPR discussions in the unwell oncology patient
Presenter: Raghad Elghadi
Session: Poster Display session 1
Resources:
Abstract
4165 - The Relation between the Symptom Burden of Hospitalized Patients with Incurable Cancer and the Quality-of-Life of Their Family Caregivers
Presenter: Eman Tawfik
Session: Poster Display session 1
Resources:
Abstract
1784 - Clinical predictors for analgesic response to radiotherapy in patients with painful bone metastases
Presenter: Ragnhild Habberstad
Session: Poster Display session 1
Resources:
Abstract
5323 - 30-Day Mortality in Palliative Radiotherapy
Presenter: Shing Fung Lee
Session: Poster Display session 1
Resources:
Abstract
3942 - The relationship between Naldemedine administration and the maximum dose of oral opioids
Presenter: Shinya Kajiura
Session: Poster Display session 1
Resources:
Abstract
3698 - Exposure to low energy amplitude modulated radiofrequency electromagnetic fields (EMF) is associated with rapid improvement in quality of life (QoL) status in patients with advanced hepatocellular carcinoma (HCC), using various analyses of EORTC-C30.
Presenter: Elizabeth Santana
Session: Poster Display session 1
Resources:
Abstract
3885 - Olanzapine Combined with 5-HT3 RA Plus Dexamethasone for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in High and Moderate Emetogenic Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Presenter: Jian-Guo Zhou
Session: Poster Display session 1
Resources:
Abstract
5700 - Early Palliative care in advanced cancer, is it really effective?
Presenter: Raquel Gómez Bravo
Session: Poster Display session 1
Resources:
Abstract
5924 - Deprescribing Potentially Inappropriate Medication in Cancer Patients
Presenter: Simon Reuter
Session: Poster Display session 1
Resources:
Abstract
5314 - Spirituality and religious coping for Cancer patients and providers: An ‘Almighty’ belief for palliative care
Presenter: Vibhay Pareek
Session: Poster Display session 1
Resources:
Abstract